VS
Vijay K Singh
Also known as: Vijay
Amity University, Uniformed Services University of the Health Sciences F Edward Hébert School of Medicine, Central Drug Research Institute, Chhatrapati Shahu Ji Maharaj University, Magadh University
Research areas: Medicine · Radiology, Nuclear Medicine and Imaging · Effects of Radiation Exposure · Radiation Therapy and Dosimetry · Immunotoxicology and immune responses
0000-0002-6631-3849
About
Dr. Vijay K. Singh is a tenured Professor at Uniformed Services University of Health Sciences (USUHS), and a Principal Investigator at Armed Forces Radiobiology Research Institute (AFRRI), Bethesda, Maryland, USA. He is a well-recognized scientist in the area of Radiation Countermeasure development. His research interests have focused on the development of radiation countermeasures for acute radiation syndrome (ARS) and delayed effects of acute radiation exposure (DEARE), understanding the mechanism of radiation injury, and identification of biomarkers for radiation injury and countermeasure efficacy. He has made significant contributions for developing several promising radiation countermeasures for ARS. He has published 260 peer reviewed research articles in high impact journals, 23 book chapters, and 320 abstracts. He is well-funded by various funding agencies of US Department of War (CDMRP, JPEO, DTRA, JPC, DMRDP) and Department of Health and Human Services (BARDA, NIAID).
He is a subject matter expert for several national and international professional committees. He reviews grant application for various national and international funding agencies, and manuscripts for large number of reputed journals. He is member of several professional societies and recipient of a large number of awards. He is also editorial board member for several journals. He serves as a member of NATO RTG (HFM-359, HFM-444) and teaches during NATO StTARS workshop. He is the Secretary for RTG (HFM-444).
After completing his Ph.D. from Central Drug Research Institute, Lucknow, India, Dr. Singh received his formal post-doctoral training at USUHS, NEI, and NCI/NIH. Previous to his current position, he served Sanjay Gandhi Post-Graduate Institute of Medical Sciences, Lucknow, India as an Additional Professor. Since 2001, Prof. Singh is at School of Medicine, USUHS and AFRRI. In 2024, he was conferred Honorary Professor by Amity University, India.
Employment
-
Amity University Honorary Professor2024 - Present
-
Uniformed Services University of the Health Sciences F Edward Hébert School of Medicine Tenured Professor2015 - Present
-
Uniformed Services University of the Health Sciences F Edward Hébert School of Medicine Tenured Associate Professor and Acting Chair2012 - 2015
-
Armed Forces Radiobiology Research Institute Principal Investigator2005 - Present
-
F. Edward Hébert School of Medicine Tenure Track Assistant Professor2005 - 2012
-
Armed Forces Radiobiology Research Institute Investigator – Immunologist2003 - 2005
-
Armed Forces Radiobiology Research Institute National Academy of Science - National Research Council Senior Research Associate, Radiation Casualty Management Team2001 - 2003
-
Sanjay Gandhi Post Graduate Institute of Medical Sciences Additional Professor1995 - 2004
-
Sanjay Gandhi Post Graduate Institute of Medical Sciences Associate Professor1990 - 1995
-
Sanjay Gandhi Post Graduate Institute of Medical Sciences Assistant Professor1989 - 1990
-
National Eye Institute, NIH Visiting Associate1987 - 1989
-
Uniformed Services University of the Health Sciences Research Associate1986 - 1987
Education
- 1979 - 1983
-
Kanpur University M.Sc.
-
Magadh University B.Sc.
Projects & Funding
-
Evaluation of L-histidine as a medical countermeasure in mixed-field radiation combined burn injury Armed Forces Radiobiology Research Institute, Uniformed Services University2026 - 2027
-
Multi-omics-based biomarkers for radiation injury and countermeasure efficacy: Validation across nonhuman primate species Armed Forces Radiobiology Research Institute, Uniformed Services University2025 - 2027
-
Development of angiogenin as a novel radiation medical countermeasure for acute radiation syndrome National Institute of Allergy and Infectious Diseases2025 - 2030
-
Multi-omics-based biomarkers for radiation injury: Validation across radiation qualities and animal models. Armed Forces Radiobiology Research Institute, Uniformed Services University2024 - 2026
-
Development of the radioprotectant BIO 300 Injectable Suspension for the prevention of H-ARS Transforming Technology for the Warfighter Initiative2024 - 2027
-
Development of gamma-tocotrienol as a radiation countermeasure for hematopoietic acute radiation syndrome Defense Health Agency2023 - 2027
-
Advanced development of BIO 300 oral tablets as a prophylactic medical countermeasure for acute radiation syndrome Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense2023 - 2027
-
Development of PLX-R18 cell therapy as a countermeasure for hematopoietic acute radiation syndrome National Institute of Allergy and Infectious Diseases2023 - 2025
-
Further development of 5-AED (androstenediol, Neumune) for the protection from acute radiation syndrome (ARS) Congressionally Directed Medical Research Programs2023 - 2026
-
Microbiome study using irradiated nonhuman primate model and a promising radioprotector under development, BIO 300 Armed Forces Radiobiology Research Institute, Uniformed Services University2022 - 2025
-
Development of BIO 300 Injectable suspension to treat radiation-induced lung injury Congressionally Directed Medical Research Programs (through Humanetics Corporation)2022 - 2027
-
Novel Biologic Countermeasure for Acute Radiation Syndrome. Defense Health Agency (through Technology Holding)2022 - 2026
-
Development for a novel countermeasure, RadioDefender, as a radioprotector for hematopoietic acute radiation syndrome Defense Health Agency (through Zymeron Corporation)2022 - 2026
-
Proteomic biomarkers for radiation injury and countermeasure efficacy National Institute of Allergy and Infectious Diseases2021 - 2026
-
Biomarkers for radiation injury and countermeasure efficacy: Proteomic approach Armed Forces Radiobiology Research Institute, Uniformed Services University2021 - 2024
-
Screening of countermeasure in NHPs analysis for countermeasure efficacy bio-markers Armed Forces Radiobiology Research Institute, Uniformed Services University2021 - 2028
-
Biomarkers for the development of BIO 301 as a prophylactic radiation countermeasure for the acute and delayed effects of radiation exposure. Joint Program Committee-72020 - 2026
-
Novel biologic countermeasure for acute radiation syndrome Defense Health Agency2020 - 2022
-
Development of radiation countermeasures using organ-on-chip model Armed Forces Radiobiology Research Institute, Uniformed Services University2019 - 2022
-
Biomarkers for radiation exposure and countermeasure efficacy: Omics studies Armed Forces Radiobiology Research Institute, Uniformed Services University2019 - 2023
-
Development of anti-ceramide scFv as mitigator of the radiation GI syndrome. NIAID, SBIR phase 22019 - 2021
-
Development of BIO 301 to prevent acute radiation syndrome and mitigate the delayed effects of acute radiation exposure. Congressionally Directed Medical Research Programs - JWMRP2019 - 2025
-
Preclinical development and testing of a new drug substance from 5‐androstenediol for radiation prophylaxis Transforming Technology for the Warfighter Initiative2018 - 2020
-
Development of Bio 301: An encapsulated nano-genistein therapy. Congressionally Directed Medical Research Programs2018 - 2022
-
Evaluation of efficacy of GT3 novel formulation: Bone marrow targeting Liposome Armed Forces Radiobiology Research Institute, Uniformed Services University2017 - 2020
-
Biomarkers for radiation injury: Integrative omics study Armed Forces Radiobiology Research Institute, Uniformed Services University2016 - 2020
-
Advanced development of BIO 300 for acute radiation syndrome and delayed effects of acute radiation exposure. Congressionally Directed Medical Research Programs/Joint Program Committee-72016 - 2024
-
Advanced development of gamma-tocotrienol as a radiation countermeasure. Congressionally Directed Medical Research Programs2015 - 2021
-
Determination of radiation dose response for the AFRRI LINAC and subsequent non-clinical studies to evaluate potential medical countermeasures as mitigators of hematopoietic and/or low dose GI syndromes (H-ARS; GI-ARS) in an NHP model. Biomedical Advanced Research and Development Authority2015 - 2024
-
Evaluation of radiation mitigators in nonhuman primates with supportive care. National Institute of Allergy and Infectious Diseases2015 - 2024
-
A pilot proof of concept (POC) non-clinical study to determine efficacy and safety using “Ex-RAD® (ON 01210.Na) as a mitigator of hematopoietic and low dose GI syndromes (H-ARS; GI-ARS) in a NHP hematopoietic injury model Biomedical Advanced Research and Development Authority2014 - 2015
-
Advanced development of Ex-RAD as a radiomitigator Defense Medical Research and Development Program2014 - 2017
-
Characterization and validation of biomarkers of Ex-RAD, a promising radiation countermeasure Armed Forces Radiobiology Research Institute, Uniformed Services University2013 - 2016
-
Mobilized progenitors as radiation countermeasure: integrative omics study Armed Forces Radiobiology Research Institute, Uniformed Services University2011 - 2014
-
Preclinical development of a bridging therapy for radiation injury Armed Forces Radiobiology Research Institute, Uniformed Services University2010 - 2013
-
Development of anti-ceramide reagents as mitigators of the acute radiation gastrointestinal syndrome Defense Medical Research and Development Program2010 - 2014
-
Use of myeloid progenitors to attenuate radiation-induced GI injury Defense Threat Reduction Agency2009 - 2013
-
Develop radiation injury model: Gottingen minipig (Sus scrofa domestica) National Institute of Allergy and Infectious Diseases2009 - 2010
-
Evaluate radiation countermeasure efficacy against neutron/gamma mixed field radiation National Institute of Allergy and Infectious Diseases2009 - 2010
-
Advanced drug development of γ-tocotrienol as a radiation countermeasure in Rhesus macaque non-human primates Defense Threat Reduction Agency2008 - 2013
-
A non-specific immunomodulator in therapy of combined injury induced sepsis in mice Armed Forces Radiobiology Research Institute, Uniformed Services University2008 - 2010
-
Analysis of cytokines in the samples of efficacy study with cGMP CBLB502 in non-human primates Cleveland Biolabs2008 - 2010
-
Evaluation of a novel synthetic lipopeptide (CBLB613) as a radiation countermeasure for GI syndrome Defense Threat Reduction Agency2008 - 2009
-
Mechanism of action of radiation countermeasures acting through toll-like receptors Armed Forces Radiobiology Research Institute, Uniformed Services University2008 - 2011
-
Evaluation of CBLB502 efficacy against γ-irradiation in non-human primates Cleveland BioLabs2008 - 2015
-
Evaluation of CBLB612 mobilized hematopoietic stem cells against γ-irradiation in non-human primates Cleveland Biolabs2008 - 2009
-
Evaluation of pharmacokinetics, pharmacodynamics and immunogenicity of CBLB502 in non-human primates Cleveland Biolabs2007 - 2008
-
Radioprotective efficacy of tocopherol succinate Armed Forces Radiobiology Research Institute, Uniformed Services University2007 - 2010
-
Modulation of inflammatory marker human C-reactive protein by ionizing radiation and 5-androstenediol Radiation Countermeasures Center of Research Excellence2007 - 2008
-
Radiobiology research and development projects with AFRRI: Evaluate radiation countermeasure efficacy against neutron/gamma mixed field radiation National Institute of Allergy and Infectious Diseases2007 - 2008
-
Evaluation of mouse myeloid progenitor cell (mMPC) as a Radiation Countermeasure Cellerant Therapeutics2007 - 2010
-
Mechanisms of action of radiation countermeasure 5-AED in Laboratory Mouse Armed Forces Radiobiology Research Institute, Uniformed Services University2006 - 2009
-
Radioprotective mechanisms of truncated flagellin (CBLB502) Defense Threat Reduction Agency2006 - 2009
-
Evaluation of radiation countermeasure candidates: Mouse survival and cytokine profiles Defense Threat Reduction Agency2005 - 2008
-
Radioprotective mechanisms of 5-androstenediol: Studies with dendritic cells Armed Forces Radiobiology Research Institute, Uniformed Services University2005 - 2008
-
Radiation protection by α-tocopherol succinate: molecular, cellular and animal studies USA Medical Research and Medical Command2003 - 2006
-
Research and development of a novel, chemically engineered radioprotectant, ON01210 of the Novonex-Ex/Rad drug family: Preclinical studies and mechanism of action USA Medical Research and Medical Command2003 - 2005
-
Anti-ceramide scFv prophylaxis of the radiation GI syndrome Congressionally Directed Medical Research Programs
-
Medical Countermeasure Drug Discovery and Development Increment 3 Defense Health Agency
Publications (265)
- Serum miRNA Profiling in BIO 300-Treated Rhesus Macaques After Total-Body Irradiation: Treatment-Associated Signatures and Candidate Pre-terminal miRNAs Save
- Serum Proteomic Signatures in Nonhuman Primates after Treatment with a Radiation Countermeasure and Exposure to a Partial- or Total-body Supralethal Radiation Dose Save
- Spleen Transcriptome of Nonhuman Primates Exposed to High Doses of Total- or Partial-Body Radiation Comparisons with Jejunum and Lung Save
- Blood-Based Biomarkers for the Preterminal Stage Using Rhesus Macaques Exposed to Acute Total-Body Radiation Save
- Serum microRNA Analysis of Nonhuman Primates Prophylaxed with Gamma-tocotrienol and Exposed to Total- or Partial-body Radiation Save
- A recombinant melanin-associated molecule as a novel and efficacious biologic countermeasure for acute radiation syndrome Save
- Longitudinal Serum Proteomic Profiling of Nonhuman Primates Exposed to Total-body Gamma Radiation and Treated with BBT-059. Save
- γ-radiation reduces phosphorylated-tau in rhesus macaque brains: potential implications for Alzheimer's disease and other tauopathies. Save
- Multiphasic blood transcriptomic signatures of radioprotection by BIO 300, a synthetic genistein nanosuspension, in a nonhuman primate model of acute radiation syndrome Save
- Proteomic Studies in Rhesus Nonhuman Primates Administered a Promising Radiation Medical Countermeasure under Development, BBT-059. Save
- Comparative study of pathology of various organs of rhesus macaques exposed to two different doses of acute total-body radiation Save
- Radiation Countermeasure Gamma-Tocotrienol Inhibits Accumulation of Lipid Peroxidation Products in the Serum of Nonhuman Primates Exposed to Partial- or Total-Body Radiation—A Hallmark of Inhibition of Irradiation-Induced Ferroptosis? Save
- Multi-faceted approach for identifying biomarkers for radiation injury and regulatory approval of radiation medical countermeasures Save
- Cutting-edge animal models for radiation combined injury drug development Save
- Development of PLX-R18, a promising and novel countermeasure for radiation-associated injuries Save
- Analysis of the Metabolomic Profile in Serum of Mice Treated with RadioDefender, a Novel Radiation Medical Countermeasure. Save
- Prophylactic Administration of BIO 300, A Radiation Medical Countermeasure, Improves Erythrocyte-Associated Parameters in the Rhesus Macaque Model Save
- Characterization of rhesus macaque model for cobalt-60 gamma-radiation source without use of blood product. Save
- Serum Metabolomic Signatures in Nonhuman Primates Treated with a Countermeasure and Exposed to Partial- or Total-Body Radiation Save
- New opportunities and current challenges using animal models for the discovery of novel countermeasures for acute radiation syndrome Save